EW Edwards Lifesciences Corp

Cwm LLC increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 105.4% in the third quarter, acquiring an additional 43,065 shares to own a total of 83,916 shares valued at $6,526,000. Several other hedge funds also adjusted their holdings in EW. Wall Street analysts maintain a "Moderate Buy" consensus rating with a target price of $93.95 for Edwards Lifesciences.

Representative Josh Gottheimer (D-New Jersey) recently sold shares of BHP Group Limited Sponsored ADR (NYSE:BHP) valued between $1,001 and $15,000 on November 19, 2025. This transaction was part of several recent trades by the Representative involving various companies. BHP Group currently has a "Hold" consensus rating from Wall Street analysts, with institutional investors like SIH Partners and Goldman Sachs increasing their stakes despite the recent sale by Gottheimer.

Barclays analyst Matt Miksic reiterated a Hold rating on Johnson & Johnson (JNJ) with a $217.00 price target. This comes as the company reported strong Q3 revenues of $23.99 billion and a net profit of $5.15 billion, exceeding last year's figures. Insider sentiment is neutral, though one director recently purchased 1,250 shares.

Barclays analyst Matt Miksic maintained a Hold rating on Johnson & Johnson (JNJ) with a $217.00 price target, and Goldman Sachs maintained a Buy rating. The company reported quarterly revenues of $23.99 billion and a net profit of $5.15 billion for the quarter ending September 28. Corporate insider sentiment on the stock is neutral, despite a recent insider purchase.

Mirova US LLC has reduced its stake in Edwards Lifesciences Corporation by 3.7%, valuing its remaining 2.8 million shares at approximately $219.47 million, making it their 20th largest holding. Despite recent insider selling, Edwards Lifesciences exceeded quarterly EPS and revenue estimates, prompting analyst upgrades and a "Moderate Buy" consensus rating with a $93.95 price target. The company also provided optimistic FY2025 EPS guidance, signaling strong financial performance moving forward.

Analysts from TD Cowen and Citi have issued bullish ratings for healthcare stocks Natera (NTRA), Immunome (IMNM), and Edwards Lifesciences (EW). Natera and Immunome received "Strong Buy" consensus ratings with significant upside potential based on current price targets. Edwards Lifesciences holds a "Moderate Buy" consensus with a projected 10.9% upside.